Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q4651377> ?p ?o }
Showing triples 1 to 21 of
21
with 100 triples per page.
- Q4651377 subject Q8255322.
- Q4651377 subject Q8431759.
- Q4651377 abstract "Zoptarelin doxorubicin consists of doxorubicin linked to a small peptide agonist to the luteinizing hormone-releasing hormone (LHRH) receptor. It has been developed as a potential treatment for a number of human cancers. The LHRH receptor is aberrantly present on the cell surface of approximately 80% of endometrial and ovarian cancers, 86% of prostate cancers and about 50% of breast cancers. Whereas in normal tissues, expression of this receptor is mainly confined to the pituitary gland, reproductive organs and hematopoietic stem cells. To a lesser extent the LHRH receptor is also found on the surface of bladder, colorectal, and pancreatic cancers, sarcomas, lymphomas, melanomas, and renal cell carcinomas.The proposed method of action is that upon administration zoptarelin doxorubicin binds to the LHRH receptor and is subsequently internalized, concentrating the toxic doxorubicin within cancer cells and the small subset of normal tissues, as opposed to the completely systemic distribution observed with untargeted chemotherapeutics. The specific targeting of the doxorubicin to LHRH receptor bearing cells is also proposed to reduce the cardiotoxicity observed in the administration of unconjugated doxorubicin.Zoptarelin doxorubicin is also known as AEZS-108 (previously AN-152).Zoptarelin doxorubicin was developed by Andrew V. Schally while at the Tulane University School of Medicine, New Orleans and subsequently at the Sylvester Comprehensive Cancer Center, University of Miami. The U.S. Food and Drug Administration (FDA) has granted it orphan drug status for ovarian cancer and endometrial cancer.".
- Q4651377 thumbnail Zoptarelin_doxorubicin.svg?width=300.
- Q4651377 wikiPageWikiLink Q141147.
- Q4651377 wikiPageWikiLink Q14864006.
- Q4651377 wikiPageWikiLink Q172341.
- Q4651377 wikiPageWikiLink Q18936.
- Q4651377 wikiPageWikiLink Q204711.
- Q4651377 wikiPageWikiLink Q7851947.
- Q4651377 wikiPageWikiLink Q8255322.
- Q4651377 wikiPageWikiLink Q8431759.
- Q4651377 wikiPageWikiLink Q944777.
- Q4651377 type ChemicalSubstance.
- Q4651377 type Drug.
- Q4651377 type ChemicalObject.
- Q4651377 type Thing.
- Q4651377 type Q8386.
- Q4651377 comment "Zoptarelin doxorubicin consists of doxorubicin linked to a small peptide agonist to the luteinizing hormone-releasing hormone (LHRH) receptor. It has been developed as a potential treatment for a number of human cancers. The LHRH receptor is aberrantly present on the cell surface of approximately 80% of endometrial and ovarian cancers, 86% of prostate cancers and about 50% of breast cancers.".
- Q4651377 label "Zoptarelin doxorubicin".
- Q4651377 depiction Zoptarelin_doxorubicin.svg.